OKYO
OKYO Pharma Ltd
1.50$
+0.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | +24.6% | +323.3% | – | – | – | – | +30.4% | +2,644.9% | +119.3% | -82.2% | +62.9% | +1.8% | -33.7% | -29.0% | |
| – | -95.2% | +57.8% | -13.8% | +429.7% | +61.3% | +5.6% | -87.2% | -45.0% | -81.5% | -76.9% | +1,092.7% | -28.1% | +1,398.0% | +215.7% | -25.2% | -12.9% | -34.4% | +118.4% | |
| – | – | – | – | – | – | – | – | – | – | – | -89.0% | -94.4% | +696.6% | -21.2% | – | – | – | – | |
| – | -69.6% | -132.9% | – | – | -310.9% | – | – | – | -491.2% | – | +395.0% | +5.5% | +460.1% | -198.0% | – | -32.3% | -39.1% | -138.7% | |
| – | -74.5% | -100.0% | – | – | +104.6% | +48.3% | -74.1% | -85.3% | -7.5% | -99.7% | +30.4% | +280.4% | +38.0% | -76.0% | +254.5% | -99.9% | +40,166.7% | +403.3% | |
| – | +299.8% | – | +39.9% | -114.1% | +74.3% | +47.5% | -74.0% | -87.9% | +12.0% | -99.7% | +30.4% | +9,931.2% | -86.3% | -90.8% | +254.5% | – | – | +497,092.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | +0.0% | +0.0% | – | -100.0% | – | -100.0% | – | -100.0% | |
| – | -81.6% | -73.6% | -3,990.7% | – | -6.1% | +20.0% | -96.4% | -96.7% | -64.2% | +17,405.9% | +0.0% | +24.4% | +712.5% | -72.5% | +333.0% | -33.4% | -57.2% | +842.2% | |
| – | -142.2% | – | -158.8% | – | -278.5% | – | – | – | – | – | – | – | – | -163.0% | – | -339.4% | – | +1,675.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.